EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association of Selected STAT Inhibitors with Prolactin-Induced Protein (PIP) in Breast Cancer

Karolina Jabłońska iD, Alicja Kmiecik, Katarzyna Nowińska iD, Aleksandra Piotrowska iD, Jarosław Suchański iD, Katarzyna Ratajczak-Wielgomas iD, Aleksandra Partyńska iD, Hanna Romanowicz, Beata Smolarz iD, Rafał Matkowski iD, Piotr Dzięgiel

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26041416 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Karolina Jabłońska und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Histology and Embryology, Department of Human Morphology and Embryology, Faculty of Medicine, Wroclaw Medical University, 50-368 Wroclaw,…. Hauptthemen laut MEDLINE: Breast Neoplasms, STAT5 Transcription Factor, Protein Inhibitors of Activated STAT, Molecular Chaperones. Die Arbeit nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Ministry of Science and Higher Education in the "Regional Initiative of Excellence programme for the years 2019-2022", The Ministry of Science and Higher Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer (BC) is the most common cancer in women, and a higher level of prolactin-induced protein (PIP) is associated with better responses to adjuvant chemotherapy. The signal transducer and activator of transcription 5 (STAT5) is a potential regulator of the PIP gene. Prolactin (PRL) and its receptor (PRLR) activate JAK2/STAT5 signaling in BC, which is modulated by inhibitors like suppressors of cytokine signaling (SOCS) proteins and protein inhibitors of activated STAT (PIAS). Using real-time PCR and immunohistochemistry, we studied the relationship between PIP and STAT5 inhibitors in BC. Our findings indicated that PIP and STAT5 levels decrease with a higher tumor grade, size, and tumor/nodes/metastasis (TNM) clinical stage, while nuclear PIAS3 levels increase with tumor progression. Both STAT inhibitors are linked to estrogen and progesterone receptor status. Notably, STAT5 correlates positively with PIP, SOCS3, and PIAS3, suggesting that it may be a favorable prognostic factor. Among the STAT inhibitors, only nuclear PIAS3 expression correlates with PIP. In vitro studies indicated that silencing PIAS3 in T47D cells does not affect PIP expression or sensitivity to doxorubicin (DOX), but T47D control cells with a higher PIP expression are more sensitive to DOX, highlighting the need for further investigation into these mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsSTAT5 Transcription FactorProtein Inhibitors of Activated STATMolecular ChaperonesCarrier ProteinsHumansFemaleCell Line, TumorMiddle AgedGene Expression Regulation, NeoplasticSuppressor of Cytokine Signaling 3 ProteinAdultSignal TransductionAgedProlactinMembrane Transport Proteins

Stichwörter der Autor:innen

GCDFP-15PIAS3PIPSOCS3STATbreast cancerprolactinprolactin-induced proteinsignal transducer and activator of transcription

Substanzen

STAT5 Transcription FactorProtein Inhibitors of Activated STATPIP protein, humanPIAS3 protein, humanMolecular ChaperonesSuppressor of Cytokine Signaling 3 ProteinCarrier ProteinsProlactinSOCS3 protein, humanMembrane Transport Proteins

Autor:innen und Institutionen

  • Division of Histology and Embryology, Department of Human Morphology and Embryology, Faculty of Medicine, Wroclaw Medical University, 50-368 Wroclaw, Poland.
  • Department of Biochemistry and Molecular Biology, Wroclaw University of Environmental and Life Sciences, 50-375 Wroclaw, Poland.
  • Department of Pathology, Polish Mother Memorial Hospital-Research Institute, 93-338 Lodz, Poland.
  • Department of Oncology, Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland.
  • Lower Silesian Oncology, Pulmonology and Hematology Center, 53-413 Wroclaw, Poland.
  • Department of Human Biology, Faculty of Physiotherapy, Wroclaw University of Health and Sport Sciences, 51-612 Wroclaw, Poland.

ORCID-Profile: Karolina Jabłońska, Katarzyna Nowińska, Aleksandra Piotrowska, Jarosław Suchański, Katarzyna Ratajczak-Wielgomas, Aleksandra Partyńska, Beata Smolarz, Rafał Matkowski

Förderung

  • The Ministry of Science and Higher Education in the "Regional Initiative of Excellence programme for the years 2019-2022"
  • The Ministry of Science and Higher Education

Zitieren

APA

Jabłońska, K., Kmiecik, A., Nowińska, K., Piotrowska, A., Suchański, J., Ratajczak-Wielgomas, K., Partyńska, A., Romanowicz, H., Smolarz, B., Matkowski, R., & Dzięgiel, P. (2025). Association of Selected STAT Inhibitors with Prolactin-Induced Protein (PIP) in Breast Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26041416

Vancouver

Jabłońska K, Kmiecik A, Nowińska K, Piotrowska A, Suchański J, Ratajczak-Wielgomas K, et al. Association of Selected STAT Inhibitors with Prolactin-Induced Protein (PIP) in Breast Cancer. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26041416

BibTeX
@article{Jaboska2025,
  author = {Jabłońska, Karolina and Kmiecik, Alicja and Nowińska, Katarzyna and Piotrowska, Aleksandra and Suchański, Jarosław and Ratajczak-Wielgomas, Katarzyna and Partyńska, Aleksandra and Romanowicz, Hanna and Smolarz, Beata and Matkowski, Rafał and Dzięgiel, Piotr},
  title = {Association of Selected STAT Inhibitors with Prolactin-Induced Protein (PIP) in Breast Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26041416}
}
Kostenlos starten →